Abstract
BackgroundThis study aims to identify dengue neutralizing antibody response in patients with dengue from a well-characterized cohort during an outbreak in central Brazil, 2012–2013.MethodsWe analyzed paired samples from 40 patients with severe dengue and 20 patients with dengue. Eligibility criteria were: IgM, NS1Ag and/or RT-PCR positivity and positive IgG result. Plaque reduction neutralization test (PRNT50) from DENV-1 to DENV-4 was performed to identify serotype-specific NAbs response. An infecting serotype was defined as ≥4-fold increase in DENV NAbs in paired samples. Monotypic response was classified as PRNT50 ≥ 1/20 to only one DENV serotype, and multitypic response was considered to be PRNT50 ≥ 1/20 to two or more serotypes simultaneously.ResultsPatients were mainly adults. Virological dengue infection was confirmed by RT-PCR: DENV-4(n = 14) and DENV-1(n = 10). Forty-four out of 60(73.3 %) patients had NAbs to DENV-4, DENV-1(68.3 %), DENV-2(68.3 %) and DENV-3(61.6 %) respectively. Fifteen percent of the cases presented monotypic response, whereas 85 % had multitypic response. DENV-4 infected-patients presented the greatest difference in PRNT50 titers compared with other serotypes. Pre-existing DENV NAbs was not correlated with disease severity. This was the first time that DENV-4 was implicated in an epidemic in the region.ConclusionOur data indicates high exposure of multiple DENV serotypes in all age groups in the pre-dengue vaccine era and also previous to Zika virus introduction in Brazil.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-016-1867-6) contains supplementary material, which is available to authorized users.
Highlights
This study aims to identify dengue neutralizing antibody response in patients with dengue from a well-characterized cohort during an outbreak in central Brazil, 2012–2013
Sixty subjects with paired samples of dengue confirmed cases were selected for the PRNT50 to all four DENV serotypes
Hemorrhagic manifestation was predominant among the severe dengue cases, a statistical significant association when compared to dengue cases (X2 = 22.85; p < 0.01)
Summary
This study aims to identify dengue neutralizing antibody response in patients with dengue from a well-characterized cohort during an outbreak in central Brazil, 2012–2013. In the American region, nearly 61 % of the 2.38 million dengue cases were reported in Brazil in 2013 [3]. Nationwide there was evidence of an upward trend in the number of reported dengue cases, hospitalization and deaths in the last decade [4,5,6]. In central Brazil the first dengue outbreak was registered in 1994 with the detection of DENV-1, followed by DENV-2 (1998), DENV-3 (2002) and DENV-4 (2011) [7, 8]. Over the last two decades the peak of dengue transmission occurred de Teive e Argolo et al BMC Infectious Diseases (2016) 16:546 in 2013 with ~55 thousand cases registered with an incidence rate of 4411 per 100,000 inhabitants [9]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have